Home » NEKTAR IN PACT TO ACQUIRE AEROGEN
NEKTAR IN PACT TO ACQUIRE AEROGEN
Nektar Therapeutics said Monday it signed a definitive agreement to acquire Aerogen Inc. in a deal worth about $32 million. Nektar (NKTR: news, chart, profile) , a San Carlos, Calif.-based drug-delivery developer, said it will pay $8 million in cash and about $24 million in stock, while retaining the option of paying the full buyout price in cash. Common shares of Aerogen (AEGN: news, chart, profile) are traded on the pink sheets. Under the terms of the deal, each Aerogen common share will be exchanged for about 75 cents per share, while each Aerogen A-1 preferred share will be exchanged for approximately $29.03 a share.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May